| # | Title | Journal | Year | Citations |
|---|
| 1 | Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer | Journal of Clinical Oncology | 2005 | 461 |
| 2 | Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology | Lancet Oncology, The | 2015 | 340 |
| 3 | Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer – A study based on the EORTC trial 22881–10882 ‘boost versus no boost’ | European Journal of Cancer | 2008 | 199 |
| 4 | Prognostic factors for patients with hepatic metastases from breast cancer | British Journal of Cancer | 2003 | 177 |
| 5 | Importance of Radiotherapy in the Outcome of Patients With Primary CNS Lymphoma: An Analysis of the CHOD/BVAM Regimen Followed by Two Different Radiotherapy Treatments | Journal of Clinical Oncology | 2002 | 144 |
| 6 | Importance of Radiotherapy in the Outcome of Patients With Primary CNS Lymphoma: An Analysis of the CHOD/BVAM Regimen Followed by Two Different Radiotherapy Treatments | Journal of Clinical Oncology | 2002 | 114 |
| 7 | A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response | British Journal of Haematology | 2000 | 101 |
| 8 | Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors | International Journal of Radiation Oncology Biology Physics | 2004 | 100 |
| 9 | A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens | British Journal of Cancer | 2007 | 98 |
| 10 | Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma | European Journal of Haematology | 2003 | 95 |
| 11 | Overexpression of FLIPL Is an Independent Marker of Poor Prognosis in Colorectal Cancer Patients | Clinical Cancer Research | 2007 | 89 |
| 12 | CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin’s lymphoma | International Journal of Radiation Oncology Biology Physics | 2001 | 84 |
| 13 | Somatic KIT mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease: Report of 220 tumors and review of literature | Genes Chromosomes and Cancer | 2008 | 83 |
| 14 | Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy. | Journal of Clinical Oncology | 1996 | 74 |
| 15 | Primary central nervous system lymphoma – Biological aspects and controversies in management | European Journal of Cancer | 2007 | 60 |
| 16 | A prototype methodology combining surface-enhanced laser desorption/ionization protein chip technology and artificial neural network algorithms to predict the chemoresponsiveness of breast cancer cell lines exposed to Paclitaxel and Doxorubicin underin vitro conditions | Proteomics | 2003 | 55 |
| 17 | The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study | Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin | 2007 | 42 |
| 18 | A Neoadjuvant/Adjuvant Randomized Trial of Colorectal Cancer Patients Vaccinated with an Anti-Idiotypic Antibody, 105AD7, Mimicking CD55 | Clinical Cancer Research | 2006 | 31 |
| 19 | Non-Hodgkin's lymphoma in elderly patients: a phase II study of MCOP chemotherapy in patients aged 70 years or over with intermediate- or high-grade histology | European Journal of Cancer | 1994 | 30 |
| 20 | Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)? | Cancer Immunology, Immunotherapy | 2005 | 30 |
| 21 | Increasing age at diagnosis and worsening renal function in patients with primary central nervous system lymphoma | Journal of Neuro-Oncology | 2011 | 30 |
| 22 | Long-term survival after treatment for Hodgkin’s disease (1973–2002): improved survival with successive 10-year cohorts | British Journal of Cancer | 2012 | 29 |
| 23 | Selective Inhibition of the Human tie-1 Promoter with Triplex-Forming Oligonucleotides Targeted to Ets Binding Sites | Molecular Medicine | 2006 | 24 |
| 24 | A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor (‘SPROG’ trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN | Annals of Oncology | 2015 | 24 |
| 25 | Routine Use of Continuous, Hyperfractionated, Accelerated Radiotherapy for Non–Small-Cell Lung Cancer: A Five-Center Experience | International Journal of Radiation Oncology Biology Physics | 2008 | 23 |
| 26 | Beyond cancer: changes, problems and needs expressed by adult lymphoma survivors attending an out-patients clinic | European Journal of Cancer Care | 1994 | 22 |
| 27 | Allogeneic Haemopoietic Stem Cell Transplantation for Multiple Myeloma or Plasma Cell Leukaemia Using Fractionated Total Body Radiation and High-dose Melphalan Conditioning | Acta Oncológica | 2000 | 21 |
| 28 | Successful management of elderly breast cancer patients treated without radiotherapy | World Journal of Surgical Oncology | 2007 | 21 |
| 29 | Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission | Bone Marrow Transplantation | 2003 | 18 |
| 30 | A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin’s lymphoma | Annals of Oncology | 2003 | 16 |
| 31 | A comparison of late cosmetic results following two different radiotherapy techniques for treating basal cell carcinoma | Clinical Oncology | 1997 | 15 |
| 32 | Severe hypoglycaemia caused by raised insulin-like growth factor II in disseminated breast cancer | Journal of Clinical Pathology | 1999 | 15 |
| 33 | Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate | British Journal of Cancer | 2012 | 15 |
| 34 | Platinum-based Chemotherapy in Metastatic Breast Cancer: The Leicester (UK) Experience | Clinical Oncology | 2005 | 11 |
| 35 | Radiotherapy as sole adjuvant treatment for older patients with low-risk breast cancer | Breast | 2012 | 10 |
| 36 | Postoperative radiotherapy following mastectomy for high-risk breast cancer | European Journal of Cancer | 2002 | 8 |
| 37 | Raised Serum Urea Predicts for Early Death in Small Cell Lung Cancer | Clinical Oncology | 2008 | 8 |
| 38 | Vascular Endothelial Growth Factor Expression Predicts Outcome after Primary Radiotherapy for Head and Neck Squamous Cell Cancer | Clinical Oncology | 2007 | 6 |
| 39 | Second-line chemotherapy for ovarian cancer | Lancet Oncology, The | 2003 | 5 |
| 40 | High-dose melphalan followed by radical radiotherapy for the treatment of massive plasmacytoma of the chest wall | Bone Marrow Transplantation | 2003 | 3 |
| 41 | The use of topotecan for relapsed ovarian cancer in accordance with the National Institute for Clinical Excellence guidance 2001: the Nottingham experience | Clinical Oncology | 2004 | 3 |
| 42 | External Beam Radiotherapy for Extensive Genital Condyloma Acuminate: a Role in Selected Patients? | Clinical Oncology | 2008 | 3 |
| 43 | Hodgkin disease (1973–2002): long-term survival and cure fractions | Leukemia and Lymphoma | 2015 | 3 |
| 44 | The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2 | Oncotarget | 2017 | 2 |
| 45 | Breast pain | BMJ: British Medical Journal | 1995 | 2 |
| 46 | Non-traumatic neurological emergencies presenting to the intensive care unit | British Journal of Hospital Medicine (London, England: 2005) | 2011 | 1 |
| 47 | Long-Term Medical Follow-Up (for More than 15 Years) of a Patient with Stage IA Mycosis Fungoides Originally Presenting in Childhood: Remission for >15 Years with Localised Electron Beam Therapy | Case Reports in Dermatological Medicine | 2021 | 0 |
